GlassScriptPhysician profile
Bleselda G Paragas
NPI 1437348265
$8,130.56
in general payments reported to CMS, 2019-2025
25 companies · $1,863 in 2025
The $1,863 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $687 · 2022: $1,875 · 2023: $1,996 · 2024: $1,709 · 2025: $1,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,918 · Education: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,917.53 |
| Education | $650.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,525.09 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Abbvie INC. | $1,155.37 | 2021-2025 | |
| Janssen Biotech, INC. | $1,122.15 | 2021-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $574.70 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $541.01 | 2021-2025 | |
| Incyte Corporation | $487.58 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $440.16 | 2022-2025 | Sotyktu |
| Ucb, INC. | $320.78 | 2021-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $261.08 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $246.42 | 2021-2025 | Libtayo |
| Dermavant Sciences, INC. | $216.29 | 2023-2024 | Vtama |
| Almirall LLC | $198.34 | 2021-2023 | Seysara |
| Genzyme Corporation | $180.46 | 2022-2025 | |
| Amgen INC. | $176.87 | 2021-2024 | Otezla, Enbrel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.62 | 2023-2025 | Spevigo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $129.63 | 2022-2024 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $104.01 | 2021-2024 | Duobrii, Siliq, Targretin |
| Arcutis Biotherapeutics, INC. | $79.16 | 2023-2025 | Zoryve |
| Organon LLC | $51.25 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $44.84 | 2025 | Nemluvio |
| Biofrontera INC. | $43.49 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Kerecis Limited | $38.50 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Journey Medical Corporation | $35.85 | 2022 | |
| Kyowa Kirin, INC. | $19.89 | 2025 | |
| Mayne Pharma Commercial LLC | $5.02 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bleselda Paragas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.